Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 24.29% is 16% below its 5-year average of 28.82%, near the low end of its 5-year range (19.01%–38.56%).
As of the fiscal period ended Tuesday, June 30, 2026. 2.28% above its 12-month average of 23.75%.
Reported quarterly debt to assets ratio; no daily interpolation. Q4 FY2026 (2026-06-30): 24.29%.
DEBT TO ASSETS RATIO
24.29%
DEBT TO ASSETS RATIO AVG TTM
23.75%
DEBT TO ASSETS RATIO AVG 3Y
26.60%
DEBT TO ASSETS RATIO AVG 5Y
28.82%
DEBT TO ASSETS RATIO AVG 10Y
25.66%
DEBT TO ASSETS RATIO AVG 15Y
15.11%
DEBT TO ASSETS RATIO AVG 20Y
15.42%
CURRENT VS TTM AVG
+2.28%
CURRENT VS 3Y AVG
-8.70%
CURRENT VS 5Y AVG
-15.71%
CURRENT VS 10Y AVG
-5.35%
CURRENT VS 15Y AVG
+60.74%
CURRENT VS 20Y AVG
+57.47%
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+26888.54%
vs the sector median at left
Pro-Dex, Inc.
Market Cap
$208.17M
Debt to Assets Ratio
24.29%
TTM Avg
23.75%
3Y Avg
26.60%
5Y Avg
28.82%
Market Cap
$209.05M
Debt to Assets Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$206.37M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$206.24M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$210.21M
Debt to Assets Ratio
0.16%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$204.79M
Debt to Assets Ratio
0.20%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$214.10M
Debt to Assets Ratio
0.12%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pro-Dex, Inc. (PDEX) | $208.17M | 24.29% | 23.75% | 26.60% | 28.82% |
| Electra Therapeutics Inc. (ETRA)vs › | $209.05M | N/A | N/A | N/A | N/A |
| Sionna Therapeutics, Inc. (SION)vs › | $206.37M | 0.03% | N/A | N/A | N/A |
| Whitehawk Therapeutics Inc (WHWK)vs › | $206.24M | 0.00% | N/A | N/A | N/A |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.21M | 0.16% | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $211.33M | 0.02% | N/A | N/A | N/A |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $204.79M | 0.20% | N/A | N/A | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $214.10M | 0.12% | N/A | N/A | N/A |
| Exagen Inc. (XGN)vs › | $202.17M | 0.49% | N/A | N/A | N/A |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $214.63M | 0.00% | N/A | N/A | N/A |
Debt/Assets
24.3%
Debt/Equity
0.38
Current Ratio
4.10
Interest Coverage
16.0x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 24.29% |
| 2026-03-31 | 26.90% |
| 2025-12-31 | 19.01% |
| 2025-09-30 | 21.45% |
| 2025-06-30 | 27.09% |
| 2025-03-31 | 30.48% |
| 2024-12-31 | 29.49% |
| 2024-09-30 | 27.64% |
| 2024-06-30 | 24.99% |
| 2024-03-31 | 25.80% |
| 2023-12-31 | 27.08% |
| 2023-09-30 | 26.96% |
| 2023-06-30 | 25.82% |
| 2023-03-31 | 30.03% |
| 2022-12-31 | 30.58% |
| 2022-09-30 | 31.63% |
| 2022-06-30 | 32.53% |
| 2022-03-31 | 33.58% |
| 2021-12-31 | 35.07% |
| 2021-09-30 | 36.22% |
| 2021-06-30 | 38.56% |
| 2021-03-31 | 37.03% |
| 2020-12-31 | 30.73% |
| 2020-09-30 | 22.04% |
| 2020-06-30 | 22.56% |
| 2020-03-31 | 24.61% |
| 2019-12-31 | 25.01% |
| 2019-09-30 | 26.51% |
| 2019-06-30 | 17.85% |
| 2019-03-31 | 18.39% |
| 2018-12-31 | 20.27% |
| 2018-09-30 | 19.98% |
| 2018-06-30 | 0.21% |
| 2018-03-31 | 0.26% |
| 2017-12-31 | 0.48% |
| 2017-09-30 | 0.58% |
| 2017-06-30 | 0.73% |
| 2017-03-31 | 0.86% |
| 2016-12-31 | 0.98% |
| 2016-09-30 | 1.35% |
| 2016-06-30 | 0.65% |
| 2016-03-31 | 0.66% |
| 2015-12-31 | 4.78% |
| 2015-09-30 | 4.83% |
| 2015-06-30 | 0.81% |
| 2015-03-31 | 0.86% |
| 2014-12-31 | 0.10% |
| 2014-09-30 | 0.11% |
| 2014-06-30 | 0.13% |
| 2014-03-31 | 0.16% |
| 2013-12-31 | 0.18% |
| 2013-09-30 | 0.19% |
| 2013-06-30 | 0.19% |
| 2013-03-31 | 0.20% |
| 2012-12-31 | 0.00% |
| 2012-09-30 | 0.00% |
| 2012-06-30 | 6.04% |
| 2012-03-31 | 5.99% |
| 2011-12-31 | 6.22% |
| 2011-09-30 | 6.80% |
| 2011-06-30 | 7.27% |
| 2011-03-31 | 8.36% |
| 2010-12-31 | 9.17% |
| 2010-09-30 | 9.36% |
| 2010-06-30 | 20.27% |
| 2010-03-31 | 16.82% |
| 2009-12-31 | 18.26% |
| 2009-09-30 | 18.80% |
| 2009-06-30 | 20.21% |
| 2009-03-31 | 20.77% |
| 2008-12-31 | 21.17% |
| 2008-09-30 | 21.31% |
| 2008-06-30 | 18.39% |
| 2008-03-31 | 12.76% |
| 2007-12-31 | 11.41% |
| 2007-09-30 | 12.07% |
| 2007-06-30 | 14.17% |
| 2007-03-31 | 19.11% |
| 2006-12-31 | 19.58% |
| 2006-09-30 | 16.27% |
| 2006-06-30 | 19.39% |
| 2006-03-31 | 20.84% |
| 2005-12-31 | 0.00% |
| 2005-09-30 | 0.00% |
| 2005-06-30 | 0.00% |
| 2005-03-31 | 0.00% |
| 2004-12-31 | 0.00% |
| 2004-09-30 | 1.16% |
| 2004-06-30 | 1.34% |
| 2004-03-31 | 1.68% |
| 2003-12-31 | 4.66% |
| 2003-09-30 | 9.29% |
| 2003-06-30 | 7.05% |
| 2003-03-31 | 8.92% |
| 2002-12-31 | 6.63% |
| 2002-09-30 | 5.09% |
